# OnCo record number-needed-to-screen (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/number-needed-to-screen/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "number-needed-to-screen" ;
  schema:name "Number needed to screen (and number needed to diagnose)"@en ;
  schema:alternateName "NNS"@en, "number needed to invite"@en, "number needed to diagnose"@en, "NND"@en, "number needed to treat to prevent one prostate cancer death"@en ;
  schema:description "How many men have to be offered the test for one man to be saved from dying of prostate cancer, and how many extra cancers have to be found along the way. In the big European trial the answer at sixteen years was 570 men invited and 18 extra cancers diagnosed per death prevented, and the figures get better the longer the trial runs."@en ;
  schema:url <https://onco.cc/terms/number-needed-to-screen/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa0810084>, <https://doi.org/10.1016/j.eururo.2019.02.009>, <https://doi.org/10.1056/nejmoa0810696>, <https://doi.org/10.1001/jama.2018.3710> ;
  onco:tag "gu", "prostate-glossary" ;
  onco:related <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/overtreatment/>, <https://onco.cc/terms/overdiagnosis/>, <https://onco.cc/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/>, <https://onco.cc/key-papers/paper-hugosson-eur-urol/>, <https://onco.cc/technologies/prostate-screening-psa-mri/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:sections <https://onco.cc/fronts/early-detection/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/prostate-screening-psa-mri/> ;
  onco:terms <https://onco.cc/terms/screening/>, <https://onco.cc/terms/overdiagnosis/>, <https://onco.cc/terms/overtreatment/>, <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/>, <https://onco.cc/key-papers/paper-hugosson-eur-urol/>, <https://onco.cc/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/>, <https://onco.cc/key-papers/paper-uspstf-prostate-screening-jama-2018/> .